Drug Recalls and Warning Letters - Increasing Numbers Caused by Manufacturing Errors and Regulatory Non-compliance Issues - GBI Research Reports

Drug Recalls and Warning Letters - Increasing Numbers Caused by Manufacturing Errors and Regulatory Non-compliance Issues

Drug Recalls and Warning Letters - Increasing Numbers Caused by Manufacturing Errors and Regulatory Non-compliance Issues - GBI Research Reports
Drug Recalls and Warning Letters - Increasing Numbers Caused by Manufacturing Errors and Regulatory Non-compliance Issues
Published Nov 07, 2011
128 pages — Published Nov 07, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs report, Drug Recalls and Warning Letters - Increasing Numbers Caused by Manufacturing Errors and Regulatory Non-compliance Issues, provides in-depth analysis of Warning Letters, drug recalls issued or reported with the US Food and Drug Administration (FDA) and its constituent agencies. The report analyzes warning letters from the issuing agencies and reason for these warning letters. The report contains year by year detailed analysis about warning letters issued for various reasons by regulatory authorities. The report is built on data and information sourced from the FDA database of warning letters and drug recalls and in-house analysis by GBI Researchs team of industry experts.

GBI Research indicates that the warning letters and drug recalls have significantly increased during 2007-2010, due to various underlying causes which are explained in detail in the report. The report also provides analysis of warning letters individually issued by the Center for Drug Evaluation (CDER), the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), the Center for Food Safety and Applied Nutrition (CFSAN), and the Center for Veterinary Medicine (CVM). The increase in the number of warning letters can be attributed to manufacturing defects present in recalled products. In the report, detailed analysis of recalled products, with the year of recall, recalling firm, dosage form, therapy area, reason for recall and the subset reason for recalls, is provided.

The report presents the year by year drug recall analysis by the recalling firms along with the reason for recall. In the analysis Class I drug recalls have been specially covered, while analysis for other types of recall have also been made. The report analyzes the percentage distribution of drug recalls in terms of dosage form, therapy area and other areas.

Scope

- The data and numerical figures on the number of warning letters and drug recalls issued according to the year of recall, recalling firm, and reporting FDA agency for 2007-2010.
- Analysis of leading therapeutic areas and dosage forms for major drug recalls were issued
- Analysis of reasons for recall, along with in-depth analysis of underlying reasons and showing its pattern from 2007-2010.
- In this report the warning letters and drug recalls were analyzed by drug class of the recalled drug products.

Reasons to buy

- Understand the pattern of warning letters and drug recalls, along with their underlying causes, so as to enable you to undertake various strategies in order to protect products from encountering safety issues.
- To analyze the major reasons for recall, along with the therapy areas and class of recalled drugs most vulnerable, so as to strengthen the areas which may lead to quality defects in your companys products.
- Reinforce quality and manufacturing strategies so as to be complaint with the current regulatory norms.
- Develop key strategic initiatives by understanding the key focus areas of the warning letters and drug recalls.

  
Source:
Document ID
GBIHC117MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents35
  List of Tables51
  List of Figures62
Drug Recalls and Warning Letters - Introduction82
  Report Guide91
Warning Letters - An Overview102
  Boxed Warning111
Warning Letters - Trend Analysis1244
  Warning Letters Reported by FDA Agency by Year121
    Warning Letters Reported by CDER1321
    Warning Letters Reported by CBER344
    Warning Letters Reported by CDRH381
    Warning Letters Reported by CFSAN391
    Warning Letters Reported by CVM401
  Warning Letters Reported by FDA Agency by Reason412
    Warning Letters Reported by FDA Agency by Reason, 2010431
    Warning Letters Reported by FDA Agencies by Reason, 2009441
    Warning Letters Reported by FDA Agencies by Reason, 2008451
    Warning Letters Reported by FDA Agencies by Reason, 2007461
  Warning Letters by Reason by Year471
    Warning Letters Reported for Regulatory Errors471
    Warning Letters Reported for Clinical Research Errors481
    Warning Letters Reported for Marketing Errors491
    Warning Letters Reported for Manufacturing Errors501
    Warning Letters Reported for Quality Errors511
  Warning Letters by Year by FDA Agency521
    Warning Letters Reported by FDA Agency in 2007521
    Warning Letters Reported by FDA Agency in 2008531
    Warning Letters Reported by FDA Agency in 2009541
    Warning Letters Reported by FDA Agency in 2010551
Drug Recalls - An Overview568
  Types of Drug Recalls561
  Reasons of Drug Recalls571
  Drug Recall Process572
  Drug Recalls Reported by CDER592
  Drug Recalls Reported by CBER613
Drug Recalls - Trend Analysis6462
  Analysis of Drug Recalls 2007-20106412
    Reasons for Drug Recall761
    Drug Recalls by Product Class771
    Drug Recalls by Different Dosage Forms781
    Drug Recalls by Companies792
    Drug Recalls by Drug Class812
    Drug Recalls by Therapy Area832
  Analysis of Drug Recalls 2007851
    Drug Recalls by Therapy Area, 2007851
    Drug Recalls by Drug Class, 2007861
    Drug Recalls by Product Class, 2007871
    Drug Recalls by Dosage Form, 2007881
    Drug Recalls by Companies, 2007891
    Reasons for Drug Recalls, 2007903
  Analysis of Drug Recalls 2008931
    Drug Recalls by Therapy Area, 2008932
    Drug Recalls by Drug Class, 2008952
    Drug Recalls by Product Class, 2008971
    Drug Recalls by Dosage Form, 2008981
    Drug Recalls by Companies, 2008992
    Reasons for Drug Recalls, 20081013
  Analysis of Drug Recalls 20091041
    Drug Recalls by Therapy Area, 20091042
    Drug Recalls by Drug Class, 20091061
    Drug Recalls by Product Class, 20091071
    Drug Recalls by Dosage Form, 20091082
    Drug Recalls by Companies, 20091101
    Reasons for Drug Recalls, 20091113
  Analysis of Drug Recalls 20101141
    Drug Recalls by Therapy Area, 20101142
    Drug Recalls by Drug Class, 20101162
    Drug Recalls by Product Class, 20101181
    Drug Recalls by Dosage Form, 20101191
    Drug Recalls by Companies, 20101201
    Reasons for Drug Recalls, 20101213
  Analysis of Top Reasons for Drug Recalls, 2007-20101241
    Drug Recalls Reported due to Manufacturing Errors1241
    Drug Recalls Reported due to Quality Defects1251
Drug Recalls and Warning Letters - Appendix1263
  Market Definitions1261
  Abbreviations1261
  Research Methodology1262
    Coverage1261
    Warning Letters An Overview1271
    Warning Letters Trend Analysis1271
    Drug Recalls An Overview1271
    Drub Recalls Trend Analysis1271
  Contact Us1281
  Disclaimer1281
  Sources1281

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Drug Recalls and Warning Letters - Increasing Numbers Caused by Manufacturing Errors and Regulatory Non-compliance Issues" Nov 07, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Drug-Recalls-and-Warning-Letters-Increasing-Numbers-Caused-by-Manufacturing-Errors-and-Regulatory-Non-compliance-Issues-2115-300>
  
APA:
GBI Research Reports. (2011). Drug Recalls and Warning Letters - Increasing Numbers Caused by Manufacturing Errors and Regulatory Non-compliance Issues Nov 07, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Drug-Recalls-and-Warning-Letters-Increasing-Numbers-Caused-by-Manufacturing-Errors-and-Regulatory-Non-compliance-Issues-2115-300>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.